Steve Wooding

Steve Wooding is an experienced pharmaceutical and medical professional with a strong background in drug development and market access strategy. Currently serving as a Special Advisor at Beckley Psytech since February 2019, Steve focuses on developing treatments for neuropsychiatric conditions from psychedelic compounds. In addition, Steve holds the position of Director at Edipol Pharmaceutical Consulting Ltd and has served as Principal Consultant at XNK Therapeutics. Prior to these roles, Steve had a notable tenure at The Janssen Pharmaceutical Companies of Johnson & Johnson from February 2007 to March 2019, where responsibilities included Head of Global Commercial and Market Access Strategy and various VP roles in EMEA. Steve's academic credentials include a Bachelor of Medicine, Bachelor of Surgery from Queen Mary University of London, an MBA from Henley Business School, a Diploma in Pharmaceutical Medicine from the University of Wales, and a Bachelor of Science in Pharmacology from the University of London.